Ocular Therapeutix Inc. [OCUL] moved up 3.77: Why It’s Important

Related

Share

Ocular Therapeutix Inc. [NASDAQ: OCUL] closed the trading session at $6.88 on 11/24/21. The day’s price range saw the stock hit a low of $6.5521, while the highest price level was $7.00. The company report on November 15, 2021 that Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will participate at the following conferences:.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Jefferies London Healthcare ConferencePresentation: Pre-recorded fireside chat will be made available on-demand beginning on Thursday, November 18th at 8:00 AM GMT / 4:00 AM ET1x1 Meetings: Friday, November 19, 2021.

The stocks have a year to date performance of -66.76 percent and weekly performance of 2.53 percent. The stock has been moved at -52.91 percent over the last six months. The stock has performed -3.10 percent around the most recent 30 days and changed -35.34 percent over the most recent 3-months.

If compared to the average trading volume of 1.14M shares, OCUL reached to a volume of 893937 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Ocular Therapeutix Inc. [OCUL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OCUL shares is $21.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OCUL stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Ocular Therapeutix Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 10, 2021. The new note on the price target was released on December 28, 2020, representing the official price target for Ocular Therapeutix Inc. stock. Previously, the target price had yet another raise to $27, while Berenberg analysts kept a Buy rating on OCUL stock. On November 13, 2020, analysts increased their price target for OCUL shares from 15 to 25.

The Average True Range (ATR) for Ocular Therapeutix Inc. is set at 0.52, with the Price to Sales ratio for OCUL stock in the period of the last 12 months amounting to 13.70. The Price to Book ratio for the last quarter was 6.04, with the Price to Cash per share for the same quarter was set at 2.33.

OCUL stock trade performance evaluation

Ocular Therapeutix Inc. [OCUL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.53. With this latest performance, OCUL shares dropped by -3.10% in over the last four-week period, additionally sinking by -52.91% over the last 6 months – not to mention a drop of -55.56% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCUL stock in for the last two-week period is set at 39.98, with the RSI for the last a single of trading hit 43.06, and the three-weeks RSI is set at 39.36 for Ocular Therapeutix Inc. [OCUL]. The present Moving Average for the last 50 days of trading for this stock 8.89, while it was recorded at 6.69 for the last single week of trading, and 13.22 for the last 200 days.

Ocular Therapeutix Inc. [OCUL]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Ocular Therapeutix Inc. [OCUL] shares currently have an operating margin of -361.13 and a Gross Margin at +80.06. Ocular Therapeutix Inc.’s Net Margin is presently recorded at -894.31.

Return on Total Capital for OCUL is now -66.07, given the latest momentum, and Return on Invested Capital for the company is -173.44. Return on Equity for this stock declined to -429.55, with Return on Assets sitting at -91.39. When it comes to the capital structure of this company, Ocular Therapeutix Inc. [OCUL] has a Total Debt to Total Equity ratio set at 76.80. Additionally, OCUL Total Debt to Total Capital is recorded at 43.44, with Total Debt to Total Assets ending up at 22.32. Long-Term Debt to Equity for the company is recorded at 64.12, with the Long-Term Debt to Total Capital now at 36.27.

Reflecting on the efficiency of the workforce at the company, Ocular Therapeutix Inc. [OCUL] managed to generate an average of -$859,867 per employee. Receivables Turnover for the company is 2.35 with a Total Asset Turnover recorded at a value of 0.10.Ocular Therapeutix Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.10 and a Current Ratio set at 8.10.

Earnings per share (EPS) analysis for Ocular Therapeutix Inc. [OCUL] stock

With the latest financial reports released by the company, Ocular Therapeutix Inc. posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OCUL.

>> 7 Top Picks for the Post-Pandemic Economy <<

Ocular Therapeutix Inc. [OCUL]: Insider Ownership positions

There are presently around $306 million, or 59.40% of OCUL stock, in the hands of institutional investors. The top three institutional holders of OCUL stocks are: OPALEYE MANAGEMENT INC. with ownership of 6,480,000, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; SUMMER ROAD LLC, holding 5,618,861 shares of the stock with an approximate value of $38.66 million in OCUL stocks shares; and BLACKROCK INC., currently with $34.21 million in OCUL stock with ownership of nearly -0.152% of the company’s market capitalization.

Positions in Ocular Therapeutix Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 65 institutional holders increased their position in Ocular Therapeutix Inc. [NASDAQ:OCUL] by around 3,360,605 shares. Additionally, 70 investors decreased positions by around 7,144,743 shares, while 29 investors held positions by with 33,971,457 shares. The mentioned changes placed institutional holdings at 44,476,805 shares, according to the latest SEC report filing. OCUL stock had 18 new institutional investments in for a total of 1,103,505 shares, while 22 institutional investors sold positions of 1,815,554 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam